Science News
from research organizations

No difference in death rates among patients exposed to common rheumatoid arthritis drugs, study suggests

Date:
August 8, 2012
Source:
Wiley
Summary:
New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade).
Share:
       
FULL STORY

New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade). This population-based study of RA patients in Sweden -- the first to compare mortality rates among patients treated with individual TNF inhibitors -- is now available in Arthritis & Rheumatism.

RA is a chronic, autoimmune disease characterized by inflammation in the joints that causes pain, tenderness and swelling. The World Health Organization estimates that RA affects up to one percent of individuals worldwide, with more than one million Americans diagnosed with the disease according to the ACR. Rheumatologists recommend early intervention with biologic disease modifying anti-rheumatic drugs (DMARDs) such as TNF inhibitors to slow disease progression, improve function, and prevent disability.

In Sweden nearly 15% of RA patients are prescribed TNF inhibitors. The present study examined the mortality rates in RA patients exposed to adalimumab, etanercept, or infliximab. "Understanding risk versus benefits of treatment with the most commonly prescribed biologics is important for physicians and patients in managing RA," said lead author Dr. Julia Fridman Simard with the Clinical Epidemiology Unit at Karolinska Institute in Stockholm, Sweden.

Researchers linked data from the Swedish Biologics Register (ARTIS), a comprehensive database of patients initiating first-ever biologic therapy for rheumatic diseases, and information from national Swedish registers that included data such as all-cause mortality, demographics, and RA characteristics. Between 2003 and 2008, 1,609 patients with RA initiated treatment with adalimumab, 2,686 with etanercept, and 2,027 with infliximab as their first ever biologic DMARD.

There were more than 19,000 person-years of follow-up during the five-year study period during which time 211 patients died (3.3%). "While we found no statistically significant difference in mortality rates across the three biologic therapies, further studies are needed to determine if this is true across certain subsets of patients with RA," concludes Dr. Simard.


Story Source:

The above post is reprinted from materials provided by Wiley. Note: Materials may be edited for content and length.


Journal Reference:

  1. Julia F Simard, Martin Neovius, Johan Askling for the ARTIS study group. Mortality in Patients with Rheumatoid Arthritis Treated with TNF Inhibitors: Drug-Specific Comparisons in the Swedish Biologics Register. Arthritis & Rheumatism, August 8, 2012 DOI: 10.1002/art.34582

Cite This Page:

Wiley. "No difference in death rates among patients exposed to common rheumatoid arthritis drugs, study suggests." ScienceDaily. ScienceDaily, 8 August 2012. <www.sciencedaily.com/releases/2012/08/120808081338.htm>.
Wiley. (2012, August 8). No difference in death rates among patients exposed to common rheumatoid arthritis drugs, study suggests. ScienceDaily. Retrieved July 28, 2015 from www.sciencedaily.com/releases/2012/08/120808081338.htm
Wiley. "No difference in death rates among patients exposed to common rheumatoid arthritis drugs, study suggests." ScienceDaily. www.sciencedaily.com/releases/2012/08/120808081338.htm (accessed July 28, 2015).

Share This Page: